Abstract
Whole brain radiation therapy (WBRT) is the standard of care for most patients with greater than four brain metastases. WBRT in these patients has been shown to improve neurologic symptoms, decrease progression of intracranial disease, and lengthen survival. In patients with one to four brain metastases, the utility of focal therapies such as neurosurgery or stereotactic radiosurgery (SRS), as well as concern over the possible neurotoxicities of WBRT, has lead to questions regarding its use in this population. However, studies looking at combined regimens of focal treatment plus WBRT vs. WBRT alone have not been able to produce conclusive evidence of either increased neurotoxicity or improved survival with the use of WBRT due to issues of lack of power, significant crossover between the randomized groups, and inconsistent endpoints. Similarly, investigations into the neurocognitive functioning of patients being treated for brain metastases have not effectively taken into account confounding factors including baseline neurologic status, radiation dose and fractionation, the effects of other palliative and anti-cancer medications, and the definition of truly clinically relevant endpoints. Two findings that have been consistently shown in these trials are that progression of disease within the brain leads to a significant decline in neurocognitive functioning, and that WBRT significantly decreases recurrence of disease within the brain. Fortunately, studies looking at various fractionation schemes have shown that there is enough flexibility in the delivery of WBRT to accommodate the patient’s overall goals of therapy while somewhat mediating the risk of unwanted effects. Finally, it is important to understand that, the shortcomings of the current body of literature notwithstanding, the process of reconciling the benefits of WBRT with the risks must include a clear perspective regarding the fact that while the concerns surrounding this therapy remain unproven, the detrimental clinical consequences of omitting WBRT are clear.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Berk L. An overview of radiotherapy trials for the treatment of brain metastases. Oncology. 1995;9(11):1205–19.
Horton J, Baxter DH, Olson KB. The management of metastases to the brain by irradiation and corticosteroids. Am J Roentgenol Radium Ther Nucl Med. 1971;111(2):334–6.
Posner JB. Management of brain metastases. Rev Neurol. 1992;148(6–7):477–87.
Cairncross JG, Posner JB. The management of brain metastases. In: Walker MD, editor. Oncology of the nervous system. Boston: Martinus Nijhoff; 1983.
Markesbery WR, Brooks WH, Gupta GD, Young AB. Treatment for patients with cerebral metastases. Arch Neurol. 1978;35(11):754–6.
Ruderman NB, Hall TC. Use of glucocorticoids in the palliative treatment of metastatic brain tumors. Cancer. 1965;18(3):298–306.
Chang DB, Yang PC, Luh KT, Kuo SH, Hong RL, Lee LN. Late survival of non-small cell lung cancer patients with brain metastases. Chest. 1992;101(5):1293–7.
Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, Perez CA, Hendrickson FR. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980;6(1):1–9.
Kwok Y, Pathchell RA, Regine WF. Management of overt central nervous system metastases: brain and spinal cord. In: Pass HI, editor. Principles and practice of lung cancer. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2010.
Gelber RD, Larson M, Borgelt BB, Kramer S. Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favorable prognosis. Cancer. 1981;48(8):1749–53.
Kurtz JM, Gelber RD, Brady LW, Carella RJ, Cooper JS. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1981;7(7):891–5.
Deiner-West M, Dobbins TW, Phillips TL, Nelson DF. Identification of an optimal subgroup for treatment evaluation of patients with brain metastases using RTOG study 7916. Int J Radiat Oncol Biol Phys. 1989;16(3):669–73.
Epstein BE, Scott CB, Sause WT, Rotman M, Sneed PK, Janjan NA, Davis LW, Selim H, Mohiuddin M, Wasserman TH. Improved survival duration in patients with unresected solitary brain metastasis using accelerated hyperfractionated radiation therapy at total doses of 54.4 gray and greater. Results of the Radiation Therapy Oncology Group 85-28. Cancer. 1993;71(4):1362–7.
Murray KJ, Scott C, Greenberg HM, Emami B, Seider M, Vora NL, Olson C, Whitton A, Movsas B, Curran W. A randomized phase III study of accelerated hyperfractionated versus standard radiation in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys. 1997;39(3):571–4.
Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan SC, Miller RA, Renschler MF. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004;22(1):157–65.
Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol. 2007;25(10):1260–6.
DeAngelis LM, Mandell LR, Thaler HT, Kimmel DW, Galicich JH, Fuks Z, Posner JB. The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery. 1989;24(6): 798–805.
Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;30(10):1080–6.
Deprez S, Amant F, Smeets A, Peeters R, Leemans A, Van Hecke W, Verhoeven JS, Christiaens MR, Vandenberghe J, Vandenbulcke M, Sunaert S. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30(3):274–81.
Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45(2):427–34.
Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran Jr WJ. Whole brain radiation therapy with and without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomized trial. Lancet. 2004;363(9422):1665–72.
Elveen T, Andrews DW. Summary of RTOG 95-01 phase III randomized trial of whole brain radiation with and without stereotactic radiosurgery boost, including presentation of a clinical case study. Am J Oncol Rev. 2004;3:592–600.
Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280(17):1485–9.
Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for the treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):2483–91.
Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037–44.
Raizer J. Radiosurgery and whole-brain radiation therapy for brain metastases. JAMA. 2006;295(21):2535–6.
Aoyama H, Tago M, Kato N, Toyoda T, Kenjyo M, Hirota S, Shioura H, Inomata T, Kunieda E, Hayakawa K, Nakagawa K, Kobashi G, Shirato H. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys. 2007;68(5):1388–95.
Mahmood U, Kwok Y, Regine WF, Patchell RA. Whole-brain irradiation for patients with brain metastases: still the standard of care. Lancet Oncol. 2010;11(3):221–2.
Regine WF, Schmitt FA, Scott CB, Dearth C, Patchell RA, Nichols Jr RC, Gore EM, Franklin 3rd RL, Suh JH, Mehta MP. Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. Int J Radiat Oncol Biol Phys. 2004;58(5):1346–52.
Armstrong CL, Corn BW, Ruffer JE, Pruitt AA, Mollman JE, Phillips PC. Radiotherapeutic effects on brain function: double dissociation of memory systems. Neuropsychiatry Neuropsychol Behav Neurol. 2000;13(2):101–11.
Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van de Berge D, Collette S, Collette L, Mueller RP. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134–41.
Pereira J, Hanson J, Bruera E. The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer. 1997;79(4):835–42.
Lawlor PG, Gagnon B, Mancini IL, Pereira JL, Hanson J, Suarez-Almazor ME, Bruera ED. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med. 2000;160(6):786–94.
Regine WF, Scott C, Murray K, Curran W. Neurocognitive outcome in brain metastases patients treated with accelerated-fraction vs. accelerated-hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group Study 91-04. Int J Radiat Oncol Biol Phys. 2001;51(3):711–7.
Regine WF, Huhn JL, Patchell RA, St Clair WH, Strottmann J, Meigooni A, Sanders M, Young AB. Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery al in patients with newly diagnosed brain metastases: results and implications. Int J Radiat Oncol Biol Phys. 2002;52(2):333–8.
Taylor BV, Buckner JC, Cascino TL, O’Fallon JR, Schaefer PL, Dinapoli RP, Schomberg P. Effects of radiation and chemotherapy on cognitive function in patients with high-grade gliomas. J Clin Oncol. 1998;16(6):2195–201.
Hocht S, Wiegel T, Hinkelbein W. Reirradiation for recurrent brain metastases. Controversies in Neuro-Oncology. Front Radiat Oncol Basal. 1999;33:327–31.
Hazuka MB, Kinzie JJ. Brain metastases: results and effects of re-irradiation. Int J Radiat Oncol Biol Phys. 1988;15(2):433–7.
Kurup P, Reddy S, Hendrickson FR. Results of re-irradiation for cerebral metastases. Cancer. 1980;46(12):2587–9.
Wong WW, Schild SE, Sawyer TE, Shaw EG. Analysis of outcome in patients reirradiated for brain metastases. Int J Radiat Oncol Biol Phys. 1996;34(3):585–90.
Cooper JS, Steinfeld AD, Lerch IA. Cerebral metastases: value of reirradiation in selected patients. Radiology. 1990;174(3 Pt 1):883–5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Regine, W.F., Grabowski, S.F., Patchell, R.A. (2015). Metastatic Brain Tumors: Viewpoint: Whole Brain Radiation Therapy. In: Chin, L., Regine, W. (eds) Principles and Practice of Stereotactic Radiosurgery. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8363-2_16
Download citation
DOI: https://doi.org/10.1007/978-1-4614-8363-2_16
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-8362-5
Online ISBN: 978-1-4614-8363-2
eBook Packages: MedicineMedicine (R0)